PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2015079329) POLYMORPHS AND PROCESS FOR PRETARATION OF (2S,5R)-7-0X0-N-[(2S)-PYRROLLIDIN-2-YL-METHYLOXY]-6-(SULFOOXY)-1,6-DIAZABICYCLO[3.2.1 ]OCTANE-2-CARBOXAMIDE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. A process for preparation of a compound of Formula (I), comprising:


Formula (I)

(a) reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound of Formula (IV);


Formula (II) Formula ( III)


Formula (IV)

(b) hydrogenolysis of a compound of Formula (IV) to obtain a compound of Formula (V);


Formula (V)

(c) converting a compound of Formula (V) to obtain a compound of Formula (VI); and


Formula (VI)

(d) converting a compound of Formula (VI) to obtain a compound of Formula

(I).

2. A process according to Claim 1, wherein compound of Formula (IV) is obtained by reacting a compound of Formula (II) with a compound of Formula (III) in presence of 1-hydroxybenzotriazole and l-ethyl-3-(3-dimethylamino propyl)carbodiimide hydrochloride.

3. A process according to Claim 1, wherein compound of Formula (IV) is obtained by reacting a compound of Formula (II) with a compound of Formula (III) in presence of mixture of water and dimethylformamide as solvent.

4. A process according to Claim 1, wherein compound of Formula (VI) is obtained by sulfonating a compound of Formula (V) with sulfur trioxide _ dimethylformamide complex, followed by treatment with tetrabutyl ammonium acetate.

5. A compound of Formula (I) in a crystalline form.

6. A compound of Formula (I) according to Claim 8, having an X-ray powder diffraction pattern comprising a peak selected the group consisting of 8.08 (± 0.2), 11.45 (± 0.2), 16.26 (± 0.2), 17.89 (± 0.2), 18.15 (± 0.2), 19.66 (± 0.2), 21.15 (± 0.2), 23.55 (± 0.2), 24.23 (± 0.2), 24.94 (± 0.2), 25.66 (± 0.2) and 29.41 (± 0.2) degrees 2 theta.

7. A compound of Formula (I) according to Claim 8, having an X-ray powder diffraction pattern comprising a peak selected the group consisting of 16.26 (± 0.2), 17.89 (± 0.2), 18.15 (± 0.2), 19.66 (± 0.2), 21.15 (± 0.2), 24.94 (± 0.2) and 25.66 (± 0.2) degrees 2 theta.

8. A compound according to Formula (I) in amorphous form.

9. (25, 5i?)-7-oxo-N-[(25)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-l,6-diazabicyclo [3.2.1]octane-2-carboxamide having a purity of at least 97% as determined by HPLC.

10. A process for preparing (25, 5i?)-7-oxo-N-[(25)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-l,6-diazabicyclo[3.2.1]octane-2-carboxamide having purity of at least 97% as determined by HPLC, said process comprising:

(a) dissolving (25, 5i?)-7-oxo-N-[(25)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-l,6-diazabicyclo[3.2.1]octane-2-carboxamide in water,

(b) adding isopropanol to the solution obtained in step (a),

(c) decanting the upper clear water isopropanol layer obtained in step (b) so as to separate it from the separated oil, and

(d) recovering crystals of (25, 5i?)-7-oxo-N-[(25)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-l,6-diazabicyclo[3.2.1]octane-2-carboxamide.